Bessard A - Search Results

1

High antitumor activity of RLI, an interleukin-15 (IL-15)-IL-15 receptor alpha fusion protein, in metastatic melanoma and colorectal cancer.

Bessard A, Solé V, Bouchaud G, Quéméner A, Jacques Y. Bessard A, et al. Mol Cancer Ther. 2009 Sep;8(9):2736-45. doi: 10.1158/1535-7163.MCT-09-0275. Epub 2009 Sep 1. Mol Cancer Ther. 2009. PMID: 19723883

2

Tumor targeting of the IL-15 superagonist RLI by an anti-GD2 antibody strongly enhances its antitumor potency.

Vincent M, Bessard A, Cochonneau D, Teppaz G, Solé V, Maillasson M, Birklé S, Garrigue-Antar L, Quéméner A, Jacques Y. Vincent M, et al. Among authors: bessard a. Int J Cancer. 2013 Aug 1;133(3):757-65. doi: 10.1002/ijc.28059. Epub 2013 Feb 25. Int J Cancer. 2013. PMID: 23354868

3

Highly potent anti-CD20-RLI immunocytokine targeting established human B lymphoma in SCID mouse.

Vincent M, Teppaz G, Lajoie L, Solé V, Bessard A, Maillasson M, Loisel S, Béchard D, Clémenceau B, Thibault G, Garrigue-Antar L, Jacques Y, Quéméner A. Vincent M, et al. Among authors: bessard a. MAbs. 2014 Jul-Aug;6(4):1026-37. doi: 10.4161/mabs.28699. MAbs. 2014. PMID: 25072059 Free PMC article.

4

RNAi-mediated MEK1 knock-down prevents ERK1/2 activation and abolishes human hepatocarcinoma growth in vitro and in vivo.

Gailhouste L, Ezan F, Bessard A, Frémin C, Rageul J, Langouët S, Baffet G. Gailhouste L, et al. Among authors: bessard a. Int J Cancer. 2010 Mar 15;126(6):1367-77. doi: 10.1002/ijc.24950. Int J Cancer. 2010. PMID: 19816936

5

GATA-1 is essential in EGF-mediated induction of nucleotide excision repair activity and ERCC1 expression through ERK2 in human hepatoma cells.

Andrieux LO, Fautrel A, Bessard A, Guillouzo A, Baffet G, Langouët S. Andrieux LO, et al. Among authors: bessard a. Cancer Res. 2007 Mar 1;67(5):2114-23. doi: 10.1158/0008-5472.CAN-06-3821. Cancer Res. 2007. PMID: 17332341

6

RNAi-mediated ERK2 knockdown inhibits growth of tumor cells in vitro and in vivo.

Bessard A, Frémin C, Ezan F, Fautrel A, Gailhouste L, Baffet G. Bessard A, et al. Oncogene. 2008 Sep 11;27(40):5315-25. doi: 10.1038/onc.2008.163. Epub 2008 Jun 2. Oncogene. 2008. PMID: 18521085

7

ERK2 but not ERK1 plays a key role in hepatocyte replication: an RNAi-mediated ERK2 knockdown approach in wild-type and ERK1 null hepatocytes.

Frémin C, Ezan F, Boisselier P, Bessard A, Pagès G, Pouysségur J, Baffet G. Frémin C, et al. Among authors: bessard a. Hepatology. 2007 Apr;45(4):1035-45. doi: 10.1002/hep.21551. Hepatology. 2007. PMID: 17393467

8

MEK/ERK-dependent uPAR expression is required for motility via phosphorylation of P70S6K in human hepatocarcinoma cells.

Bessard A, Frémin C, Ezan F, Coutant A, Baffet G. Bessard A, et al. J Cell Physiol. 2007 Aug;212(2):526-36. doi: 10.1002/jcp.21049. J Cell Physiol. 2007. PMID: 17427199

9

Multiple division cycles and long-term survival of hepatocytes are distinctly regulated by extracellular signal-regulated kinases ERK1 and ERK2.

Frémin C, Bessard A, Ezan F, Gailhouste L, Régeard M, Le Seyec J, Gilot D, Pagès G, Pouysségur J, Langouët S, Baffet G. Frémin C, et al. Among authors: bessard a. Hepatology. 2009 Mar;49(3):930-9. doi: 10.1002/hep.22730. Hepatology. 2009. PMID: 19177593

10

An MLCK-dependent window in late G1 controls S phase entry of proliferating rodent hepatocytes via ERK-p70S6K pathway.

Bessard A, Coutant A, Rescan C, Ezan F, Frémin C, Courselaud B, Ilyin G, Baffet G. Bessard A, et al. Hepatology. 2006 Jul;44(1):152-63. doi: 10.1002/hep.21222. Hepatology. 2006. PMID: 16799973

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

28 results

Search Page

Filters